EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations.
LAS VEGAS, Feb. 11, 2026 /PRNewswire/ -- DelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
EGFR-NSCLC Market Summary
Discover the new EGFR-NSCLC treatment @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the EGFR-NSCLC Market
EGFR-NSCLC Market Analysis
EGFR-NSCLC Competitive Landscape
The EGFR-NSCLC clinical trial pipeline includes several drugs in mid- and late-stage development that are expected to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others.
Cullinan Oncology/Taiho Pharma's Zipalertinib (CLN-081/TAS6417) is an innovative, orally available, irreversible EGFR inhibitor that, according to preclinical data, selectively and effectively targets cells with EGFR exon 20 insertion (EGFRex20ins) mutations while largely sparing wild-type EGFR-expressing cells, thereby minimizing the toxicities typically linked to wild-type EGFR inhibition. It features a distinct chemical structure designed for strong selectivity toward mutant EGFR and reduced activity against both wild-type EGFR and the closely related HER2 receptor. Zipalertinib holds promise as a potential new standard of care for treating non-small cell lung cancer (NSCLC) with EGFRex20ins mutations.
ArriVent BioPharma's Firmonertinib is an orally administered, brain-penetrant, mutation-selective EGFR inhibitor with broad activity against both common and uncommon EGFR alterations, including PACC and exon 20 insertion mutations. It is currently being investigated in a global Phase III clinical trial for first-line treatment of NSCLC patients harboring EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase Ib trial assessing its efficacy in patients with EGFR PACC mutations (FURTHER; NCT05364043).
The anticipated launch of these emerging therapies are poised to transform the EGFR-NSCLC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the EGFR-NSCLC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the EGFR-NSCLC drugs market @ EGFR-NSCLC Clinical Trials
Recent Developments in the EGFR-NSCLC Market
What is EGFR-NSCLC?
EGFR is a cellular protein that promotes cell growth. Mutations in the EGFR gene can lead to excessive growth, which may result in cancer. These mutations can take various forms, such as deletions, insertions, or point mutations. In clinical testing, patients may be identified as having an EGFR exon 19 deletion or an EGFR L858R point mutation; these are the most common EGFR mutations and are usually managed in the same way. However, some rarer EGFR mutations in lung cancer are treated differently from the common types. A key example is EGFR exon 20 insertions, which do not respond to standard EGFR-targeted therapies known as tyrosine kinase inhibitors (TKIs).
EGFR-NSCLC Epidemiology Segmentation
The EGFR-NSCLC epidemiology section provides insights into the historical and current EGFR-NSCLC patient pool and forecasted trends for the leading markets. In 2024, EGFR Exon 19 deletions accounted for the highest number of cases, approximately 10,000 in EGFR NSCLC in the US.
The EGFR-NSCLC treatment market report proffers epidemiological analysis for the study period 2020–2034 in the leading markets, segmented into:
EGFR-NSCLC Market Report Metrics
Details
Study Period
2020–2034
Coverage
7MM [The United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
EGFR-NSCLC Market CAGR
9.6 %
EGFR-NSCLC Market Size in 2024
USD 6 Billion
Key EGFR-NSCLC Companies
ArriVent BioPharma (NASDAQ: AVBP), Akeso Biopharma (HKG: 9926), Summit Therapeutics (NASDAQ: SMMT), J INTS BIO, Merus (NASDAQ: MRUS), Merck (NYSE: MRK), Kelun-Biotech (HKG: 6990), Genprex (NASDAQ: GNPX), Cullinan Oncology (NASDAQ: CGEM), Taiho Pharma, CSPC Pharmaceutical (HKG: 1093), AbbVie (NYSE: ABBV), Teligene, Bristol–Myers Squibb (NYSE: BMY), SystImmune, Black Diamond Therapeutics (NASDAQ: BDTX), Lantern Pharma (NASDAQ: LTRN), Dizal Pharmaceutical (SHA: 688192), Daiichi Sankyo (TYO: 4568), AstraZeneca (LON: AZN), Jiangsu Hansoh Pharmaceutical, Boehringer Ingelheim, Pfizer (NYSE: PFE), Johnson & Johnson Innovative Medicine (NYSE: JNJ), Yuhan Corporation (KRX: 000100), Eli Lilly and Company (NYSE: LLY), and others
Key EGFR-NSCLC Therapies
Firmonertinib, Ivonescimab (SMT112), JIN-A02, Pamvatamig (MCLA-129), Sacituzumab Tirumotecan (MK-2870), Quaratusugene ozeplasmid (REQORSA), Zipalertinib (CLN-081), SYS6010, Temab-A (telisotuzumab adizutecan) (ABBV-400), Sutetinib, Izalontamab Brengitecan (BMS-986507), Silevertinib (BDTX-1535), LP-300, ZEGFROVY, DATROWAY, AUMSEQA, TAGRISSO, GILOTRIF/GIOTRIF, VIZIMPRO, RYBREVANT ± LAZCLUZE, PORTRAZZA, and others
Scope of the EGFR-NSCLC Market Report
Download the report to understand the factors driving the EGFR-NSCLC market @ EGFR-NSCLC Market Analysis
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary of EGFR-NSCLC
4
Key Events
4.1
Upcoming Key Catalysts
4.2
Key Conferences and Meetings
4.3
Key Transactions and Collaborations
4.4
News Flow
5
Epidemiology and Market Forecast Methodology
6
EGFR-NSCLC Market Overview at a Glance
6.1
Clinical Landscape (Analysis by Molecule Type, Phase, and Route of Administration [RoA])
6.2
Market Share (%) Distribution of EGFR-NSCLC by Line of Therapy (LoT) in 2024 in the 7MM
6.3
Market Share (%) Distribution of EGFR-NSCLC by Line of Therapy (LoT) in 2034 in the 7MM
7
Disease Background and Overview
7.1
Introduction
7.2
Structure and Mechanism of EGFR
7.3
Types of EGFR Mutation in NSCLC
7.4
Risk Factors Associated With EGFR-mutated NSCLC
7.5
Diagnosis
7.5.1
Biomarker Testing for EGFR Mutation
7.5.2
Diagnosis Algorithm of EGFR
7.5.3
Diagnosis Guidelines
7.6
Treatment
7.6.1
Current Treatment
7.6.2
Treatment Algorithm
7.6.3
Treatment Guidelines
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale
8.3
Total Incident Cases of NSCLC in the 7MM
8.4
United States
8.4.1
Total Incident Cases of NSCLC in the United States
8.4.2
Gender-specific Cases of NSCLC in the United States
8.4.3
Age-specific Cases of NSCLC in the United States
8.4.4
Total Incident Cases of NSCLC by Histology in the United States
8.4.5
Total Incident Cases of NSCLC by Stage in the United States
8.4.6
Total Cases of EGFR-NSCLC in the United States
8.4.7
Treated Patient Pool across the Lines of Therapies in the United States
8.5
EU4 and the UK
8.5.1
Total Incident Cases of NSCLC in EU4 and the UK
8.5.2
Gender-specific Cases of NSCLC in EU4 and the UK
8.5.3
Age-specific Cases of NSCLC in EU4 and the UK
8.5.4
Total Incident Cases of NSCLC by Histology in EU4 and the UK
8.5.5
Total Incident Cases of NSCLC by Stage in EU4 and the UK
8.5.6
Total Incident Cases of EGFR-NSCLC by biomarker in EU4 and the UK
8.5.7
Total Treated Patient Pool across the Lines of Therapies in EU4 and the UK
8.6
Japan
8.6.1
Total Incident Cases of NSCLC in Japan
8.6.2
Gender-specific Cases of NSCLC in Japan
8.6.3
Age-specific Cases of NSCLC in Japan
8.6.4
Total Incident Cases of NSCLC by Histology in Japan
8.6.5
Total Incident Cases of NSCLC by Stage in Japan
8.6.6
Total Cases of EGFR-NSCLC in Japan
8.6.7
Treated Patient Pool across the Lines of Therapies in Japan
9
Patient Journey
10
Key Endpoints
11
Marketed Therapies
11.1
Key Cross of Marketed Therapies
11.2
Sunvozertinib (ZEGFROVY): Dizal Pharmaceutical
11.2.1
Product Description
11.2.2
Regulatory Milestones
11.2.3
Other Developmental Activities
11.2.4
Summary of Pivotal Trials
11.2.5
Clinical Development
11.2.6
Safety and Efficacy
11.2.7
Analyst Views
11.3
Datopotamab Deruxtecan (DATROWAY): Daiichi Sankyo/AstraZeneca
11.3.1
Product Description
11.3.2
Regulatory Milestones
11.3.3
Other Developmental Activities
11.3.4
Summary of Pivotal Trials
11.3.5
Clinical Development
11.3.6
Safety and Efficacy
11.3.7
Analyst Views
11.4
Aumolertinib (AUMSEQA): Jiangsu Hansoh Pharmaceutical
11.4.1
Product Description
11.4.2
Regulatory Milestones
11.4.3
Other Developmental Activity
11.4.4
Summary of Pivotal Clinical Trial
11.4.5
Analyst View
11.5
Osimertinib (TAGRISSO): AstraZeneca
11.5.1
Product Description
11.5.2
Regulatory Milestones
11.5.3
Other Developmental Activities
11.5.4
Summary of Pivotal Trials
11.5.5
Clinical Development
11.5.6
Safety and Efficacy
11.5.7
Analyst Views
11.6
Afatinib maleate (GILOTRIF/GIOTRIF): Boehringer Ingelheim
11.6.1
Product Description
11.6.2
Regulatory Milestones
1.1.1
Other Developmental Activities
11.6.3
Summary of Pivotal Trials
11.6.4
Safety and Efficacy
11.6.5
Analyst Views
11.7
Dacomitinib (VIZIMPRO): Pfizer
11.7.1
Product Description
11.7.2
Regulatory Milestones
11.7.3
Other Developmental Activities
11.7.4
Summary of Pivotal Trials
11.7.5
Clinical Development
11.7.6
Safety and Efficacy
11.7.7
Analyst Views
11.8
Amivantamab (RYBREVANT) ± Lazertinib (LAZCLUZE): Johnson & Johnson Innovative Medicine/Yuhan Corporation
11.8.1
Product Description
11.8.2
Regulatory Milestones
11.8.3
Other Developmental Activities
11.8.4
Pivotal Clinical Trial
11.8.5
Clinical Development
11.8.6
Safety and Efficacy
11.8.7
Analyst Views
11.9
Necitumumab (PORTRAZZA): Eli Lilly and Company
11.9.1
Product Description
11.9.2
Regulatory Milestones
11.9.3
Other Developmental Activities
11.9.4
Safety and Efficacy
11.9.5
Analyst Views
12
Emerging drugs
12.1
Key Cross Competition
12.2
Firmonertinib: ArriVent BioPharma
12.2.1
Product Description
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.4
Safety and Efficacy
12.2.5
Analyst View
12.3
Ivonescimab (SMT112): Akeso Biopharma/Summit Therapeutics
12.3.1
Product Description
12.3.2
Other Developmental Activity
12.3.3
Clinical Development
12.3.4
Safety and Efficacy
12.3.5
Analyst View
12.4
JIN-A02: J INTS BIO
12.4.1
Product Description
12.4.2
Other Developmental Activities
12.4.3
Clinical Development
12.4.4
Safety and Efficacy
12.4.5
Analyst View
12.5
Pamvatamig (MCLA-129): Merus
12.5.1
Product Description
12.5.2
Other Developmental Activities
12.5.3
Clinical Development
12.5.4
Safety and Efficacy
12.5.5
Analyst View
12.6
Sacituzumab Tirumotecan (MK-2870): Merck and Kelun-Biotech
12.6.1
Product Description
12.6.2
Other Developmental Activities
12.6.3
Clinical Development
12.6.4
Safety and Efficacy
12.6.5
Analyst View
12.7
Quaratusugene ozeplasmid (REQORSA): Genprex
12.7.1
Product Description
12.7.2
Other Developmental Activities
12.7.3
Clinical Development
12.7.4
Safety and Efficacy
12.7.5
Analyst Views
12.8
Zipalertinib (CLN-081): Cullinan Oncology/Taiho Pharma
12.8.1
Product Description
12.8.2
Other Developmental Activities
12.8.3
Clinical Development
12.8.4
Safety and Efficacy
12.2.2
Other Developmental Activities
12.2.3
Clinical Development
12.2.4
Safety and Efficacy
12.2.5
Analyst View
12.3
Ivonescimab (SMT112): Akeso Biopharma/Summit Therapeutics
12.3.1
Product Description
12.8.5
Analyst Views
12.9
SYS6010: CSPC Pharmaceutical
12.9.1
Product Description
12.9.2
Other Developmental Activities
12.9.3
Clinical Development
12.9.4
Safety and Efficacy
12.9.5
Analyst Views
12.10
Temab-A (telisotuzumab adizutecan) (ABBV-400): AbbVie
12.10.1
Product Description
12.10.2
Other Developmental Activities
12.10.3
Clinical Development
12.10.4
Safety and Efficacy
12.10.5
Analyst Views
12.11
Sutetinib: Teligene
12.11.1
Product Description
12.11.2
Clinical Development
12.11.3
Safety and Efficacy
12.11.4
Analyst Views
12.12
Izalontamab Brengitecan (BMS-986507): Bristol–Myers Squibb/SystImmune
12.12.1
Product Description
12.12.2
Other Developmental Activities
12.12.3
Clinical Development
12.12.4
Safety and Efficacy
12.12.5
Analyst View
12.13
Silevertinib (BDTX-1535): Black Diamond Therapeutics
12.13.1
Product Description
12.13.2
Other Developmental Activity
12.13.3
Clinical Development
12.13.4
Safety and Efficacy
12.13.5
Analyst View
12.14
LP-300: Lantern Pharma
12.14.1
Product Description
12.14.2
Other Developmental Activities
12.14.3
Clinical Development
12.14.4
Safety and Efficacy
12.14.5
Analyst View
13
EGFR-NSCLC: 7MM Market Analysis
13.1
Key Findings
13.2
The 7MM
13.2.1
Total Market Size of EGFR-NSCLC by Country in the 7MM
13.2.2
Market Size of EGFR NSCLC by Therapies in the 7MM
13.3
Market Outlook
13.4
Conjoint Analysis
13.5
Key Market Forecast Assumptions
13.5.1
Cost Assumptions
13.6
The United States
13.6.1
Total Market Size of EGFR NSCLC in the United States
13.6.2
Market Size of EGFR NSCLC by Therapies in the United States
13.7
EU4 and the UK
13.7.1
Total Market Size of EGFR NSCLC in EU4 and the UK
13.7.2
Market Size of EGFR NSCLC by Therapies in EU4 and the UK
13.8
Japan
13.8.1
Total Market Size of EGFR NSCLC in Japan
13.8.2
Market Size of EGFR NSCLC by Therapies in Japan
14
Unmet Needs
15
SWOT Analysis
16
KOL Views
17
Market Access and Reimbursement
17.1
The United States
17.2
In EU4 and the UK
17.2.1
Germany
17.2.2
France
17.2.3
Italy
17.2.4
Spain
17.2.5
United Kingdom
17.3
Japan
17.4
Summary and Comparison of Market Access and Pricing Policy Developments in 2025
17.5
Market Access and Reimbursement of EGRF-NSCLC Therapies
18
Appendix
18.1
Bibliography
18.2
Report Methodology
19
DelveInsight Capabilities
20
Disclaimer
21
About DelveInsight
Related Reports
EGFR-NSCLC Clinical Trial Analysis
EGFR-NSCLC Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key EGFR-NSCLC companies, including Genprex, J INTS Bio, Black Diamond Therapeutics, BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, Antares Therapeutics, Bayer, A2 Biotherapeutics, BioNTech, Dragonfly Therapeutics, Merus, Taiho Oncology, BeOne Medicines (formerly BeiGene), Ono Pharmaceutical, Avistone Biotechnology, Dizal Pharmaceuticals, Checkpoint Therapeutics, DEKA Biosciences, and Taiho Oncology among others.
Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including BeiGene, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma/Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron/Sanofi, Ono Pharmaceutical, Novartis, Genentech/Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK among others.
Non-small Cell Lung Cancer Clinical Trial Analysis
Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including ArriVent BioPharma, iTeos Therapeutics, GSK, Incyte, Macrogenics, AstraZeneca, Hutchison MediPharma, Hoffmann-La Roche, Genentech, AnaptysBio, Shanghai Henlius Biotech, Otsuka Pharmaceutical, Bristol-Myers Squibb, OSE Immunotherapeutics, Arcus Biosciences, Gilead Sciences, Pfizer, Cullinan Oncology, Taiho Pharma, ImmunityBio, Jiangsu Hansoh Pharmaceutical, Daiichi Sankyo, Boehringer Ingelheim, Moderna Therapeutics, Merck Sharp & Dohme, Eli Lilly and Company, BeyondSpring, Immutep, Genmab, Imugene, Dizal Pharmaceutical, Regeneron Pharmaceuticals, AbbVie, Candel Therapeutics, among others.
Small Cell Lung Cancer Market
Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Hoffmann-La Roche, Pharma Mar, Jazz, Daiichi Sankyo, Henlius Biotech, SN BioScience, Merck & Co, AstraZeneca, Advenchen Laboratories, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP